Replivir Tablet 0.5 mg contains Entecavir, a potent antiviral medication used for the treatment of chronic hepatitis B virus (HBV) infection in adults. Chronic HBV infection can lead to serious liver complications, including cirrhosis, liver failure, and hepatocellular carcinoma. Entecavir effectively suppresses viral replication, reduces liver inflammation, and slows disease progression, making it a key option for long-term management of chronic hepatitis B.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Replivir 0.5 mg is indicated for:

• Chronic Hepatitis B Virus Infection:
  Treatment of adult patients with evidence of active viral replication and elevated liver enzymes.

• Prevention of Liver Disease Progression:
  Reduces the risk of cirrhosis, hepatic decompensation, and hepatocellular carcinoma in patients with chronic HBV.

Therapeutic Class

Antiviral – Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI)

Pharmacology

Entecavir is a guanosine nucleoside analog that inhibits hepatitis B virus polymerase, an enzyme critical for viral DNA replication. It acts at multiple stages of viral replication, including reverse transcription, DNA synthesis, and chain elongation. By suppressing HBV replication, Entecavir reduces viral load, improves liver function, and slows the progression of liver damage. It has a high barrier to resistance, making it effective even in patients previously treated with lamivudine who have developed viral resistance.

Dosage and Administration

• The recommended dose of Replivir Tablet is 0.5 mg once daily, taken orally on an empty stomach (at least 2 hours before or after a meal).

• For patients with lamivudine-resistant HBV, a higher dose of 1 mg once daily may be recommended by a physician.

• Treatment duration is long-term and may continue indefinitely based on viral suppression, liver function tests, and physician assessment.

• Tablets should be swallowed whole with water; they should not be crushed or chewed.

• Dose adjustment may be necessary for patients with severe renal impairment.

Drug Interactions

• Entecavir has a low potential for significant drug interactions.

• Caution is advised when co-administered with other nephrotoxic or renally cleared medications.

• Antacids containing aluminum or magnesium may reduce absorption if taken simultaneously; spacing doses by at least 2 hours is recommended.

Contraindications

• Hypersensitivity to entecavir or any component of the formulation.

• Patients with decompensated liver disease should be monitored closely when initiating therapy.

Side Effects

Replivir 0.5 mg is generally well tolerated. Common side effects may include:

• Headache

• Fatigue

• Dizziness

• Nausea

• Vomiting

• Abdominal pain

• Diarrhea

Rare but serious effects include lactic acidosis, severe hepatomegaly with steatosis, and exacerbation of hepatitis after discontinuation of therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Renal Monitoring: Dose adjustment required in severe renal impairment.

• Lactic Acidosis & Hepatotoxicity: Rare but potentially life-threatening; patients should be monitored for unexplained fatigue, nausea, or abdominal pain.

• Hepatitis Flare: Severe acute exacerbations can occur after discontinuing therapy; close monitoring is essential.

• Pregnancy & Lactation: There is limited data in humans; Entecavir should be used only if clearly needed. Breastfeeding is not recommended during treatment.

Storage Conditions

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.

Mode of Action

Entecavir selectively inhibits HBV DNA polymerase, preventing viral DNA synthesis and replication. By reducing viral load and hepatic inflammation, Replivir 0.5 mg helps preserve liver function and slows progression to cirrhosis or liver cancer. Its high potency and resistance profile make it a first-line therapy for chronic hepatitis B management.